EMD-29794

Single-particle
5.6 Å
EMD-29794
3D View Gallery
Deposition: 16/02/2023
Map released: 24/01/2024
Last modified: 16/10/2024
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-29794

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-8g72 summary report (pdf.gz) Map-8g72 FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

SARS-CoV-2 spike/Nb2 complex with 1 RBD up (local refinement at 5.6 A)

EMD-29794

Single-particle
5.6 Å
EMD-29794
3D View Gallery
Deposition: 16/02/2023
Map released: 24/01/2024
Last modified: 16/10/2024
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Severe acute respiratory syndrome coronavirus 2, Vicugna pacos
Sample: SARS-CoV-2 spike/Nb2 complex with 1 RBD up
Fitted models: 8g72

Deposition Authors: Ye G, Bu F, Liu B , Li F
Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19.
Ye G, Pan R , Bu F, Zheng J, Mendoza A, Wen W, Du L , Spiller B, Wadzinski BE, Liu B , Perlman S , Li F
(2023) J Virol , 97 , e0144823 - e0144823
PUBMED: 37855638
DOI: doi:10.1128/jvi.01448-23
ISSN: 1098-5514
ASTM: JOVIAM